Everything below concerns prothymosin alpha. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-16. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
With oral administration, progesterone accounts for less than 20% of the dose in circulation while 5α- and 5β-reduced products like allopregnanolone and pregnanolone account for around 80%. With vaginal administration, progesterone accounts for around 50% of the dose and 5α- and 5β-reduced metabolites for around 40%. A small amount of progesterone is converted by 21-hydroxylase into 11-deoxycorticosterone. Increases in levels of 11-deoxycorticosterone are markedly higher when progesterone is given orally as opposed to via parenteral routes like vaginal or intramuscular injection. The conversion of progesterone into 11-deoxycorticosterone occurs in the intestines (specifically the duodenum) and in the kidneys. 21-Hydroxylase appears to be absent in the liver, so conversion of progesterone into 11-deoxycorticosterone is thought not to occur in this part of the body. Endogenous progesterone is metabolized approximately 50% into 5α-dihydroprogesterone in the corpus luteum, 35% into 3β-dihydroprogesterone in the liver, and 10% into 20α-dihydroprogesterone. Metabolites of progesterone with one or more available hydroxyl groups are conjugated via glucuronidation and/or sulfation and excreted. The biological half-life of progesterone in the circulation is very short; with intravenous injection, its half-life has ranged widely from 3 to 90 minutes in various studies. The metabolic clearance rate of progesterone ranges between 2,100 and 2,800 L/day, and is constant across the menstrual cycle.
Genome analysis reveal rifampicin resistant strains have a mutation in rpoA and rpoC. A similar study investigated the bacterial fitness associated with compensatory mutations in rifampin resistant Escherichia coli. Results obtained from this study demonstrate that drug resistance is linked to bacterial fitness as higher fitness costs are linked to greater transcription errors.
The supporters of the war claimed that it "pitted British Freedom, justice and civilization against Boer backwardness". The French Canadians' opposition to the Canadian involvement in a British 'colonial venture' eventually led to a three-day riot in Quebec. Many Canadian soldiers did not actually see combat since many arrived around the time of the signing of the Treaty of Vereeniging on 31 May 1902.
Sources: en.wikipedia.org
Kuban Cossacks are Cossacks who live in the Kuban region of Russia. Although many Cossack groups came to inhabit the Western North Caucasus, most of the Kuban Cossacks are descendants of the Black Sea Cossack Host (originally the Zaporozhian Cossacks), and the Caucasus Line Cossack Host. During the Russian Civil War, Kuban Cossacks established their own state, the Kuban People's Republic. They attempted to form a federal union with Ukraine People's Republic, but it was defeated by the White Army forces undert Anton Denikin, and eventually Kuban was overcome by the Bolsheviks.
S-(2-hydroxyacyl)glutathione + H2O = glutathione + a 2-hydroxy carboxylate This enzyme belongs to the family of hydrolases, specifically the class of thioester lyases. It is commonly known as glyoxalase II. It participates in pyruvate metabolism.
Thermolysin (EC 3.4.24.27, Bacillus thermoproteolyticus neutral proteinase, thermoase, thermoase Y10, TLN) is a thermostable neutral metalloproteinase enzyme produced by the Gram-positive bacteria Bacillus thermoproteolyticus. It requires one zinc ion for enzyme activity and four calcium ions for structural stability. Thermolysin specifically catalyzes the hydrolysis of peptide bonds containing hydrophobic amino acids. However thermolysin is also widely used for peptide bond formation through the reverse reaction of hydrolysis. Thermolysin is the most stable member of a family of metalloproteinases produced by various Bacillus species. These enzymes are also termed 'neutral' proteinases or thermolysin -like proteinases (TLPs).
Sources: en.wikipedia.org
=== Additional surface methods === The SELDI process is a combination of surface-enhanced neat desorption (SEND),surface-enhanced affinity-capture (SEAC), and surface-enhanced photolabile attachment and release (SEPAR) mass spectrometry. With SEND, analytes can be desorbed and ionized without adding a matrix; the matrix is incorporated into the sample surface. In SEAC, the sample surface is modified to bind the analyte of interest for analysis with laser desorption/ionization mass spectrometry (LDI-MS). SEPAR is a combination of SEND and SEAC; the modified sample surface also acts as an energy absorbing matrix for ionization.
== M == M13 phage - m7G(5')pppN diphosphatase - malformation - maltose-transporting ATPase - manganese-transporting ATPase - mannose-6-phosphate 6-reductase - mapping - marker - melanoma - melting - menaquinol oxidase (H+-transporting) - Johann Mendel - Mendelian inheritance - message - messenger RNA - metaphase - methylphenyltetrahydropyridine N-monooxygenase - methylsterol monooxygenase - methyltetrahydroprotoberberine 14-monooxygenase - microarray technology - microsatellite - MIMT1 - minusheet perfusion culture system - Mir-188 microRNA precursor family - Mir-615 microRNA precursor family - Mir-675 microRNA precursor family - missense mutation - mitochondrial DNA - mobility shift - molecular weight size marker - monoclonal antibody - monosaccharide-transporting ATPase - monosomy - morphine 6-dehydrogenase - mouse model - mRNA - multicistronic message - multicopy plasmid - multiple cloning site - multiple endocrine neoplasia, type 1 - mutation - myristoyl-CoA 11-(E) desaturase - myristoyl-CoA 11-(Z) desaturase -
Woods held the view that Biko had filled the vacuum within the country's African nationalist movement that arose in the late 1960s following the imprisonment of Nelson Mandela and the banning of Sobukwe. Following Biko's death, the Black Consciousness Movement declined in influence as the ANC emerged as a resurgent force in anti-apartheid politics. This brought about a shift in focus from the BCM's community organising to wider mass mobilisation, including attempts to follow Tambo's call to make South Africa "ungovernable", which involved increasing violence and clashes between rival anti-apartheid groups. Followers of Biko's ideas re-organised as the Azanian People's Organisation (AZAPO), which subsequently split into the Socialist Party of Azania and the Black People's Convention. Several figures associated with the ANC denigrated Biko during the 1980s. For instance, members of the ANC-affiliated United Democratic Front assembled outside Biko's Ginsberg home shouting U-Steve Biko, I-CIA!, an allegation that Biko was a spy for the United States' Central Intelligence Agency (CIA). These demonstrations resulted in clashes with Biko supporters from AZAPO. A year after Biko's death, his "Frank Talk" writings were published as an edited collection, I Write What I Like. The defence that Biko provided for arrested SASO activists was used as the basis for the 1978 book The Testimony of Steve Biko, edited by Millard Arnold.
== History == Before the development of the ELISA, the only option for conducting an immunoassay was radioimmunoassay, a technique using radioactively labeled antigens or antibodies. In radioimmunoassay, the radioactivity provides the signal, which indicates whether a specific antigen or antibody is present in the sample. Radioimmunoassay was first described in a scientific paper by Rosalyn Sussman Yalow and Solomon Berson published in 1960. As radioactivity poses a potential health threat, a safer alternative was sought. A suitable alternative to radioimmunoassay would substitute a nonradioactive signal in place of the radioactive signal. When enzymes (such as horseradish peroxidase) react with appropriate substrates (such as ABTS or TMB), a change in color occurs, which is used as a signal. However, the signal has to be associated with the presence of an antibody or antigen, which is why the enzyme has to be linked to an appropriate antibody. This linking process was independently developed by Stratis Avrameas and G. B. Pierce. Since it is necessary to remove any unbound antibody or antigen by washing, the antibody or antigen has to be fixed to the surface of the container; i.e., the immunosorbent must be prepared. A technique to accomplish this was published by Wide and Jerker Porath in 1966. In 1971, Peter Perlmann and Eva Engvall at Stockholm University in Sweden, and Anton Schuurs and Bauke van Weemen in the Netherlands independently published papers that synthesized this knowledge into methods to perform EIA/ELISA.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.